Insider transactions

EDGAR

ARMATA PHARMACEUTICALS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-17.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–13 of 13

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-10 Filed 2026-07-14Birx Deborah Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)14,0414.26
59,814.66

Derived: shares × price per share. Exact value 59814.66.

198,417Direct (D) No
F1
  • F1 Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Open filing 0001104659-26-083516 Read from the filing’s XML Dispute this row
2026-04-24 Filed 2026-04-28Gilmer Daniel B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (51,280) — exercise price 12.92
Acquired (A)51,2800.00
0

Derived: shares × price per share. Exact value 0.00.

51,280Direct (D) No
F1
  • F1 The Stock Option vests as to one-third of the underlying shares of common stock on each of the first, second and third annual anniversaries of the date of grant, subject to continuous service through the vesting date.
Open filing 0001104659-26-050391 Read from the filing’s XML Dispute this row
2026-03-14 Filed 2026-03-17Kyme Pierre Officer: Chief Business Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,03010.54
10,856.2

Derived: shares × price per share. Exact value 10856.20.

9,461Direct (D) No
F1
  • F1 Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Open filing 0001104659-26-029712 Read from the filing’s XML Dispute this row
2026-03-14 Filed 2026-03-17Birx Deborah Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)4,91910.54
51,846.26

Derived: shares × price per share. Exact value 51846.26.

212,458Direct (D) No
F1
  • F1 Represents shares that have been withheld by the Company to satisfy its income tax and withholding remittance obligations in connection with the net settlement of restricted stock units.
Open filing 0001104659-26-029711 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11House David Duane Officer: SVP, Finance, and PFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (109,885) — exercise price 11.61
Acquired (A)109,8850.00
0

Derived: shares × price per share. Exact value 0.00.

109,885Direct (D) No
F1
  • F1 Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.
Open filing 0001104659-26-026587 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Schlesinger Sarah J. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026581 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Odysseas Kostas D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026583 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Kramer Robin Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026589 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Haimovitz Jules Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026579 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Peterson Todd C. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026585 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11PATTI JOSEPH M Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (25,640) — exercise price 11.61
Acquired (A)25,6400.00
0

Derived: shares × price per share. Exact value 0.00.

25,640Direct (D) No
F1
  • F1 The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
Open filing 0001104659-26-026586 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Kyme Pierre Officer: Chief Business Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (183,142) — exercise price 11.61
Acquired (A)183,1420.00
0

Derived: shares × price per share. Exact value 0.00.

183,142Direct (D) No
F1
  • F1 Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.
Open filing 0001104659-26-026588 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Birx Deborah Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (421,226) — exercise price 11.61
Acquired (A)421,2260.00
0

Derived: shares × price per share. Exact value 0.00.

421,226Direct (D) No
F1
  • F1 Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.
Open filing 0001104659-26-026582 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
Innoviva, Inc. Common Stock, $0.01 par value82.755,467,459.0005/12/2026 Filed 2026-05-13SCHEDULE 13D/AAmendment 15Open filing 0001104659-26-060384 Dispute this row
Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value69.746,756,659.0005/12/2026 Filed 2026-05-13SCHEDULE 13D/AAmendment 15Open filing 0001104659-26-060384 Dispute this row
Innoviva, Inc. Common Stock, $0.01 par value83.155,467,459.0001/23/2026 Filed 2026-01-26SCHEDULE 13D/AAmendment 14Open filing 0001140361-26-002376 Dispute this row
Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value70.146,756,659.0001/23/2026 Filed 2026-01-26SCHEDULE 13D/AAmendment 14Open filing 0001140361-26-002376 Dispute this row
Innoviva, Inc. Common Stock, $0.01 par value83.355,467,45908/11/2025 Filed 2025-08-12SCHEDULE 13D/AAmendment 13Open filing 0001140361-25-030666 Dispute this row
Innoviva Strategic Opportunities LLC Common Stock, $0.01 par value7046,756,65908/11/2025 Filed 2025-08-12SCHEDULE 13D/AAmendment 13Open filing 0001140361-25-030666 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,225,847 filings read, dated 2004-06-14 to 2026-11-16: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
2022143,589
2023199,811
2024209,823
2025235,520
2026260,165

Filings made before the SEC required XML are listed, not extracted.

Back to ARMATA PHARMACEUTICALS, INC.